Background Intensity-modulated radiation therapy (IMRT) has been employed as a precision radiation therapy with higher conformity to the target. Although clinical outcomes have been reported for many investigations, detailed treatment planning results have not been mentioned to date. The aim of this study was to evaluate the dose specifications of our IMRT treatment plans for locally advanced prostate cancer. Methods Seventy-seven clinically applied IMRT plans treated between September 2003 and December 2005, in which patients were irradiated with 78 Gy in the prone position, were retrospectively analyzed. Dosimetric data output from dose volume histograms were evaluated in detail. Results The mean dose ± standard deviation, homogeneity index, and conformity index to the planning target volume (PTV) were 78.3 ± 0.7 Gy (100.4 ± 0.9%), 13.7 ± 3.0, and 0.83 ± 0.04, respectively. For the clinical target volume, the mean dose was 80.3 ± 0.7 Gy (102.9 ± 0.9%).The V40, V60, and V70 Gy of the rectal wall were 58.3 ± 2.8, 29.6 ± 2.7, and 15.2 ± 3.0%, respectively. Planning difficulties were encountered in patients whose bowels were displaced downward, as constraints imposed by the bowel position altered the dose index of the PTV. In many cases, additional bowel optimization parameters were required to satisfy constraints for organs at risk. However, major deviation could be avoided by inverse planning with computer optimization. Conclusion IMRT allowed the creation of acceptable and practical treatment plans for locally advanced prostate cancer. Reports regarding detailed dosimetric evaluations are mandatory for interpreting clinical outcomes in the future.
Introduction
Intensity-modulated radiation therapy (IMRT) has been employed as a precision radiation therapy offering higher conformity to the target [1] . IMRT can create complicated dose distributions using a computer optimization to achieve a dose escalation to the target volume and dose reduction of organs at risks (OAR) adjacent to the target. Many clinical investigations have reported dosimetric and clinical advantages of IMRT for prostate cancers [2] [3] [4] [5] [6] [7] , head-andneck tumors [8, 9] , brain tumors [10] [11] [12] , gynecologic tumors, [13] [14] [15] etc.
Especially in prostate cancer, IMRT's advantage is distinct and it is widely applied in routine clinical practice, and better clinical outcomes have been reported. However, details of treatment planning results were not mentioned in existing articles, which makes it difficult to compare outcomes among different institutions and to derive an optimal treatment planning policy from planning-outcome comparison studies. Because IMRT plans have essentially inhomogeneous dose distribution, it is very difficult to grasp the big picture of the treatment plans of IMRT based on some representative dosimetric index values alone, such as D95. Therefore, this study was aimed at revealing the dose specifications of our routine IMRT planning protocol for locally advanced prostate cancer as well as comparing IMRT to our previous three-dimensional conformal radiotherapy (3D-CRT) methods [16] .
Materials and methods

Patient characteristics
Between September 2003 and December 2005, 85 patients with T3N0M0 prostate cancer, classified using the 2002 definition of the International Union Against Cancer, were consecutively treated by IMRT at our institution. Of those, eight cases were excluded from the analysis because of the following reasons. In five of the patients, the prescribed dose was reduced from 78 to 66-74 Gy due to diabetes mellitus, previous irradiation adjacent to the prostate, or a history of surgical management of rectal cancer; two other patients were irradiated using a setup position or port arrangement different from the routine protocol, and one patient had a huge atonic neurogenic urinary bladder and required a different planning concept to the bladder. Therefore, the present study was finally conducted on the remaining 77 patients with T3N0M0 prostate cancer treated by standard IMRT plans. These patients were treated in the prone position and 78 Gy was delivered to the target. Their characteristics are given in Table 1 .
IMRT planning protocols
Patients were immobilized in the prone position using a thermoplastic shell (Hip Fix system; Med-Tec Inc., Orange City, IA, USA), which extended from mid-thigh to the upper third of the leg, in combination with a vacuum pillow (Vac-Lok system; Med-Tec Inc.) and a leg support. Planning computed tomography (CT) images were acquired using a CT simulator (CTS-20; Shimadzu, Kyoto, Japan) with a 5-mm slice thickness. Patients were instructed to void the urinary bladder and rectum about 1-1.5 h before the CT scan, according to the patient's particular condition. Setup errors were evaluated based on the pelvic bony structure with film-based portal imaging (liniacgraphy:
LG). Off-line systematic setup error correction was performed using five sequential LGs obtained before the first five irradiations, followed by weekly acquisition of LGs for setup verifications and corrections if necessary.
All plans were carried out using 15-MV photon beams delivered by a Clinac 2300 C/D (Varian Medical Systems, Palo Alto, CA, USA) with a 40-leaf pair of multileaf collimators of 1-cm thickness. Treatment plans were created using an Eclipse-Helios system (Ver. 7; Varian Medical Systems, Palo Alto, CA, USA). The final dose distributions were calculated using a pencil beam convolution algorithm with a 5 95 mm calculation grid size. The modified Batho method was applied for heterogeneity correction.
The prostate, seminal vesicles, rectal outer wall, bladder outer wall, small bowel, and large bowel were contoured. A clinical target volume (CTV) was created based on the prostate and seminal vesicles, which were contoured with reference to magnetic resonance images in most of the patients. The proximal two-thirds of the seminal vesicles were included in the CTV for T3a cases, and the entire seminal vesicles were included in the CTV for T3b patients. Inclusion of the seminal vesicles in the CTV resulted in larger CTVs in the current series than in the IMRT protocol used in a previous study, in which only the prostate was irradiated [16] . Margins for the planning target volume (PTV) were added to the CTV according to the following 3D setting: 9-mm margins universally, except for a 6-mm margin posteriorly (for the direction towards the rectum) and 10 mm superiorly (for the caudal direction). The rectal wall (RECT_W) was generated using the extract wall function of the treatment planning system (TPS), applying a 4-mm thickness. The existing RECT_W was uniform, ranging from 10 mm below the apex of the prostate to 10 mm above the tips of the seminal vesicles. The bladder wall (BLAD_W) was generated in the same manner with a 4-mm thickness. The PTV was divided into two components, with and without rectal overlap, for use in computer optimization. When the overlapping area of the PTV and bowels was large and caused difficulties in optimization, the PTV was further divided. A five-field dynamic multileaf collimator technique was used for IMRT beam delivery. Gantry angles were 0, 75, 135, 225, and 285°. Inverse treatment planning by computer optimization was conducted with the Helios system. The inverse optimizations were performed with the aim of fulfilling the planning goals establish in our planning protocol. The treatment planning goals to be achieved in the final dose distribution are listed in Table 2 . Not only these hard constraints but also the following soft constrains were taken into account in accepting the final dose distribution, after fine adjustment of a normalization value. (1) The anterior rectal wall should receive 90-100% of the prescribed dose; the 95% isodose line usually lies between the anterior border of the rectal wall and the posterior border of the PTV. (2) There should be no significant hot spots outside the PTV. (3) The 50% isodose line of the prescribed dose should generally not lie beyond the posterior wall of the rectum. These same constraints were also applied in the previous 3D-CRT plan used in our institution, in which patients were irradiated with 74 Gy. When the plan did not match the OAR constraints despite adjustments of the optimization parameters, PTV dose coverage was sacrificed to give higher priority to the OARs.
Analyses of dose statistics
Planning data were analyzed using the outputs from the dose-volume histograms (DVH) generated by the TPS. D95 (D99) was defined as the percentage of the prescribed dose covering 95% (99%) of the volume. V90 was the percentage volume that received at least 90% of the prescribed dose. V40 Gy was defined as the percentage volume that received at least 40 Gy. The dose inhomogeneity of the PTV was defined using the following equation: homogeneity index (HI) = (D5-D95)/mean dose 9 100. Dose conformity to the PTV was calculated as the conformity index (CI) advocated by van't Riet [17] : CI = (V95 PTV /V PTV ) 9 (V95 PTV /V95 BODY ). Here, V95 PTV is the V95 of the PTV, V PTV is the volume of the PTV, and V95 BODY is the body volume covered by 95% of the prescribed dose.
The patients were divided into two groups based on anatomical conditions. Group B-consisted of patients who did not need optimization constraints for the bowel, because either no or only a very small volume of bowel was included in the irradiated field. Group B? comprised patients who required additional bowel optimization parameters to satisfy the final dose constraints. Statistical calculations were performed with PRISM 4 software (GraphPad Software, San Diego, CA, USA).
Results
Treatment planning
A typical dose distribution in the trans-axial plane is shown in Fig. 1 . Figure 2 illustrates the DVH, in which the mean and standard deviations of the PTV, RECT_W, and BLAD_W are indicated. Target doses statistics are summarized in Table 3 . The mean dose (mean ± standard deviation) to the PTV was 78.3 ± 0.7 Gy (100.4 ± 0.9%), with a maximum dose of 84.7 ± 0.8 Gy (108.6 ± 1.0%). The V90, D95, and D99 were 97.3 ± 2.5, 92.4 ± 2.9, and 86.7 ± 5.6%, respectively. The HI was 13.7 ± 3.0, and the CI was 0.83 ± 0.04. For the CTV, the mean dose was 80.3 ± 0.7 Gy (102.9 ± 0.9%), and the V90, D95, and D99 were 99.9 ± 0.4, 98.7 ± 1.2, and 97.0 ± 2.3%, respectively.
Plan normalization values were adjusted to meet the dose constraints for the OAR. The doses to the RECT_W and BLAD_W are summarized in Table 4 . The V40, V60, and V70 Gy of the RECT_W were 58.3 ± 2.8, 29.6 ± 2.7, and 15.2 ± 3.0%, respectively. The V40 and V70 Gy of the BLAD_W were 41.6 ± 10.8 and 20.6 ± 5.1%, respectively.
The V65 Gy of the large bowel exceeded 0.50 ml in 13 patients (0.51-2.11 ml). However, V65 Gy exceeding 1.0 ml was observed in only one patient (2.11 ml). The V60 Gy of the small bowel [0.50 ml was observed in five patients (0.51-1.07 ml), but reached 1.0 ml in only one patient. If the initial goals could not be satisfied, the optimization parameters were relaxed to meet the clinical requirements; to meet the rectal wall constraints, the PTV coverage was sacrificed. While treatment planning goals for the OAR were achieved in most cases (Table 5) , PTV coverage could not be preserved in several patients presenting with anatomical difficulties.
Impact of the bowels on target coverage Difficulties were encountered in treatment planning for patients whose bowels were displaced downward. Figure 3 indicates the differences in the doses administered to the target volumes between the two groups. Forty-eight patients were assigned to group B?, where additional optimization parameters for the bowels were needed, while 29 cases were assigned to group B-. For the PTV, the D95, V90, and D99 in group B-versus group B? were 93.7 ± 1.2 versus 91.5 ± 3.3% (P = 0.0006), 98.6 ± 1.1 versus 96.6 ± 2.8% (P = 0.0003), and 89.6 ± 2.2 versus 84.9 ± 6.3% (P \ 0.0001), respectively. The values in group B-were significantly higher than those in Values are mean ± SD group B?. Significant differences in HI and CI were also observed. On the other hand, there was no significant difference in the mean dose of the PTV and CTV, or in the D95 of the CTV between the groups.
Discussion
IMRT has been employed as a precision radiation therapy with higher conformity to the target. Although clinical outcomes have been reported for many investigations, results of treatment planning have not been mentioned in detail to date. Therefore, the aim of this study was to evaluate the dose specifications of our IMRT treatment plans for locally advanced prostate cancer.
In an Australian study reported by Skala et al. [18] , three institutions created IMRT plans for their patients with prostate cancer using the same contours and dose constraints. While the final dose constraints could be satisfied without great difficulty, there were large differences in the DVH curves of the OAR. However, determination of interinstitutional homogeneity was incomplete due to a lack of detailed information regarding the planning concept. In the present study, clinical plans were designed at a single institute by three radiation oncologists and five medical physics personnel. Homogeneous plans could be achieved within the defined soft and hard constraints.
The process of IMRT treatment planning, in which the dose distribution is adjusted to achieve a balance between targets and OARs, differs from that of conventional radiotherapy planning. In IMRT plans, the dose distribution is essentially not homogeneous; this is not the case for 3D-CRT plans, which are difficult to adapt because they consist solely of a prescribed dose determined using simple methods that have been universally adopted in conventional radiotherapy, e.g., the point dose to the isocenter. Discrepancies between the ''official'' prescribed dose of IMRT plans and that of 3D-CRT plans occur not only through inter-institutional variation but also through intrainstitutional variation. The PTV mean doses of IMRT plans in the present study (CTV = prostate ? whole or 2/3 of seminal vesicles) and 3D-CRT plans in a previous analysis (CTV = prostate alone) were 100.4 ± 0.9% and 99.5 ± 0.3%, respectively, while the corresponding CTV values were 102.9 ± 0.9% and 100.7 ± 0.7%, respectively [16] .
Unlike the conventional radiation treatment planning with the dose prescription to the isocenter, the final dose distribution of IMRT has larger variation because inverse planning deviates from the optimization constraints; that is, the set of dosimetric values determined by the planner (e.g., prescribed dose) is one of several optimization parameters. Normalization with the D95 of the PTV overlapping the OAR may cause large differences in the PTV mean dose, depending on the volume ratio included in the OAR, and may increase treatment inhomogeneity. In contrast, the application of multiple dose constraints as applied in our protocol results in rather homogeneous mean doses to the target. In designing our planning protocol for prostate IMRT, we decided to give higher priority to avoiding potential dose escalation and larger variation in the mean dose to the target caused by the D95 dose prescription. Therefore, our 78 Gy plan was defined as plans satisfying the previously-described soft and hard constraints, which resulted in very small variations in the mean doses to both the CTV and the PTV, as indicated in Table 3 . In our planning protocol, coverage, homogeneity, and conformity were sacrificed to spare the bowels, while the CTV dose was maintained. In other words, the PTV dose was decreased to provide adequate clinical optimization. IMRT plans often require this kind of compromise to avoid extreme deviations.
In this study, rectal radiation doses were analyzed based on relative volumes, using software designed for the TPS. Munbodh et al. [19] analyzed the radiation dose on the rectum surface to identify indicators of late rectal toxicity. However, this approach poses several clinical difficulties such as the necessity for special in-house software. In contrast, evaluating the dose to the OAR based on the absolute volume appears to result in less inter-institutional deviation. Thus, details of rectal DVH analyses based on a uniform delineation and absolute volumes may serve as a useful alternative indicator. In the meantime, it is important [20, 21] . After achieving homogeneity in terms of target delineation and optimization, detailed reporting and analysis are indispensable in the interpretation and comparison of clinical outcomes [21] . This is also true within a single institute, where a thorough review of treatment planning results is essential to evaluate clinical outcome. The precise and quantitative evaluation of treatment plans may contribute to the development of new treatment protocols or guidelines in the future.
IMRT is generally more sensitive to various errors than the conventional 3D-CRT [22] . Therefore, accurate and precise beam delivery is very important in IMRT delivery. Recently, several image-guided radiotherapy (IGRT) techniques have been introduced in IMRT for prostate cancer. Prostate-based online error correction can be performed using fiducial markers, CT on rails, cone beam CT, ultrasound or electromagnetic beacon transponders [23] [24] [25] . These IGRT technologies theoretically allow margin reduction for the PTV [26] . However, their clinical adequacy should be carefully validated, because a reduction of the PTV margin from 10 (6) mm in bony-structurebased correction to 5 (3) mm in prostate-based IGRT with implanted markers in 3D-CRT for prostate cancer resulted in a decreased 5-year biochemical failure-free survival rate from 91 to 58% [27] .
In conclusion, planning outcomes of a clinical IMRT planning protocol for prostate cancer were evaluated. Several dose constraints for the PTV and OARs were sufficient to maintain planning homogeneity. In patients with downward displacement of the small and large bowels, additional optimization parameters were often required. Although this sacrificed the PTV coverage, major deviations from the constraints were avoided due to computer optimization. The precise evaluation of clinical plans, as conducted in the present study, is indispensable for understanding the inter-and intra-institutional differences Fig. 3 The differences in index values in the doses administered to the target volumes. IMRT plans were stratified depending on whether additional optimization parameters for the bowels were needed (group B?, n = 48) or not (group B-, n = 29) in clinical outcomes. This analysis provides an important basis on which to design treatment planning protocols as well as to interpret clinical outcomes of the current protocol in the future.
